RU97108070A - PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF DISEASES CAUSED BY IL-6 EDUCATION - Google Patents

PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF DISEASES CAUSED BY IL-6 EDUCATION

Info

Publication number
RU97108070A
RU97108070A RU97108070/14A RU97108070A RU97108070A RU 97108070 A RU97108070 A RU 97108070A RU 97108070/14 A RU97108070/14 A RU 97108070/14A RU 97108070 A RU97108070 A RU 97108070A RU 97108070 A RU97108070 A RU 97108070A
Authority
RU
Russia
Prior art keywords
pharmaceutical composition
antibody
treatment
prophylaxis
prevention
Prior art date
Application number
RU97108070/14A
Other languages
Russian (ru)
Other versions
RU2147442C1 (en
Inventor
Кисимото Тадамицу
Кацуме Асао
Саито Хироюки
Original Assignee
Кисимото Тадамицу
Чугаи Сейяку Кабусики Кайся
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Кисимото Тадамицу, Чугаи Сейяку Кабусики Кайся filed Critical Кисимото Тадамицу
Priority claimed from PCT/JP1995/002169 external-priority patent/WO1996012503A1/en
Publication of RU97108070A publication Critical patent/RU97108070A/en
Application granted granted Critical
Publication of RU2147442C1 publication Critical patent/RU2147442C1/en

Links

Claims (14)

1. Фармацевтическая композиция для профилактики или лечения заболеваний, вызываемых образованием интерлейкина-6, которая включает антитело к рецептору интерлейкина-6.1. A pharmaceutical composition for the prevention or treatment of diseases caused by the formation of interleukin-6, which includes an antibody to the receptor for interleukin-6. 2. Фармацевтическая композиция для профилактики или лечения по п. 1, отличающаяся тем, что заболевание, вызываемое образованием указанного интерлейкина-6, представляет собой плазмацитоз. 2. The pharmaceutical composition for prophylaxis or treatment according to claim 1, characterized in that the disease caused by the formation of said interleukin-6 is plasmacytosis. 3. Фармацевтическая композиция для профилактики или лечения по п. 1, отличающаяся тем, что заболевание, вызываемое образованием указанного интерлейкина-6, представляет собой гипериммуноглобулинемию. 3. The pharmaceutical composition for prophylaxis or treatment according to claim 1, characterized in that the disease caused by the formation of said interleukin-6 is hyperimmunoglobulinemia. 4. Фармацевтическая композиция для профилактики или лечения по п. 1, отличающаяся тем, что заболевание, вызываемое образованием указанного интерлейкина-6, представляет собой анемию. 4. The pharmaceutical composition for prophylaxis or treatment according to claim 1, characterized in that the disease caused by the formation of said interleukin-6 is anemia. 5. Фармацевтическая композиция для профилактики или лечения по п. 1, отличающаяся тем, что заболевание, вызываемое образованием указанного интерлейкина-6, представляет собой нефрит. 5. The pharmaceutical composition for prophylaxis or treatment according to claim 1, characterized in that the disease caused by the formation of said interleukin-6 is nephritis. 6. Фармацевтическая композиция для профилактики или лечения по п. 1, отличающаяся тем, что заболевание, вызываемое образованием указанного интерлейкина-6, представляет собой кахексию. 6. The pharmaceutical composition for prevention or treatment according to claim 1, characterized in that the disease caused by the formation of said interleukin-6 is cachexia. 7. Фармацевтическая композиция для профилактики или лечения по п. 2, отличающаяся тем, что указанный плазмацитоз индуцируется ревматизмом. 7. The pharmaceutical composition for prevention or treatment according to claim 2, characterized in that said plasmacytosis is induced by rheumatism. 8. Фармацевтическая композиция для профилактики или лечения по п. 2, отличающаяся тем, что указанный плазмацитоз индуцируется болезнью Кастлмана. 8. The pharmaceutical composition for prophylaxis or treatment according to claim 2, characterized in that said plasmacytosis is induced by Castleman's disease. 9. Фармацевтическая композиция для профилактики или лечения по п. 5, отличающаяся тем, что указанный нефрит представляет собой мезангиальный пролиферирующий нефрит. 9. The pharmaceutical composition for prophylaxis or treatment according to claim 5, characterized in that said nephritis is mesangial proliferating nephritis. 10. Фармацевтическая композиция для профилактики или лечения по любому из пп. 1-9, отличающаяся тем, что указанное антитело представляет собой моноклональное антитело. 10. The pharmaceutical composition for the prevention or treatment according to any one of paragraphs. 1-9, characterized in that the antibody is a monoclonal antibody. 11. Фармацевтическая композиция для профилактики или лечения по п. 10, отличающаяся тем, что указанное антитело представляет собой антитело РМ-1. 11. The pharmaceutical composition for prophylaxis or treatment according to claim 10, characterized in that said antibody is an PM-1 antibody. 12. Фармацевтическая композиция для профилактики или лечения по п. 10, отличающаяся тем, что указанное антитело представляет собой химерное антитело. 12. The pharmaceutical composition for prophylaxis or treatment of claim 10, wherein said antibody is a chimeric antibody. 13. Фармацевтическая композиция для профилактики или лечения по п. 10, отличающаяся тем, что указанное антитело представляет собой видоизмененное человеческое антитело. 13. The pharmaceutical composition for the prevention or treatment of claim 10, wherein said antibody is a modified human antibody. 14. Фармацевтическая композиция для профилактики или лечения по п. 13, отличающаяся тем, что упомянутое антитело представляет собой видоизмененное человеческое антитело РМ-1. 14. The pharmaceutical composition for prophylaxis or treatment of claim 13, wherein said antibody is a modified human PM-1 antibody.
RU97108070A 1994-10-21 1995-10-20 Pharmaceutical composition for prophylaxis or treatment of diseases caused by il-6 formation RU2147442C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP25701094 1994-10-21
JP6-257010 1994-10-21
PCT/JP1995/002169 WO1996012503A1 (en) 1994-10-21 1995-10-20 Remedy for diseases caused by il-6 production

Publications (2)

Publication Number Publication Date
RU97108070A true RU97108070A (en) 1999-05-10
RU2147442C1 RU2147442C1 (en) 2000-04-20

Family

ID=17300476

Family Applications (1)

Application Number Title Priority Date Filing Date
RU97108070A RU2147442C1 (en) 1994-10-21 1995-10-20 Pharmaceutical composition for prophylaxis or treatment of diseases caused by il-6 formation

Country Status (13)

Country Link
US (1) US20070036785A1 (en)
EP (3) EP2319535A3 (en)
JP (1) JP4896093B2 (en)
CN (4) CN1306963C (en)
CA (1) CA2203182C (en)
CZ (3) CZ296979B6 (en)
FI (3) FI121455B (en)
HK (1) HK1067062A1 (en)
HU (2) HU225392B1 (en)
NO (6) NO324046B1 (en)
PL (1) PL182089B1 (en)
RU (1) RU2147442C1 (en)
WO (1) WO1996012503A1 (en)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8017121B2 (en) 1994-06-30 2011-09-13 Chugai Seiyaku Kabushika Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
GB9702944D0 (en) * 1997-02-13 1997-04-02 Univ Manchester Reducing fibrosis
EP2011514B1 (en) 1997-03-21 2012-02-29 Chugai Seiyaku Kabushiki Kaisha A preventive or therapeutic agent for sensitized T cell-mediated diseases comprising IL-6 antagonist as an active ingredient
WO1999008707A1 (en) * 1997-08-15 1999-02-25 Chugai Seiyaku Kabushiki Kaisha Preventives and/or remedies for systemic lupus erythematosus containing anti-il-6 receptor antibody as the active ingredient
PL201461B1 (en) 1998-03-17 2009-04-30 Chugai Pharmaceutical Co Ltd Preventives or remedies for inflammatory intestinal diseases containing as the active ingredient il-6 antagonists
DE69934698T2 (en) * 1998-08-24 2007-10-04 Chugai Seiyaku K.K. MEDIUM FOR PREVENTING OR TREATING PANCREATITIS CONTAINING ANTI-IL-6 RECEPTOR ANTIBODIES AS ACTIVE COMPONENTS
DE19948126A1 (en) * 1999-10-06 2001-04-12 Max Delbrueck Centrum Pharmaceutical agent for the treatment of cachexia and / or cardiogenic shock
DK1334731T3 (en) * 2000-10-25 2008-05-26 Chugai Pharmaceutical Co Ltd Preventive or therapeutic agent for psoriasis comprising anti-IL-6 receptor antibody as active ingredient
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
NZ534542A (en) * 2002-02-14 2006-08-31 Chugai Pharmaceutical Co Ltd Antibody-containing solutions in which the formation of degradation products and insoluble particles during storage and freeze/thaw cycles is inhibited by adding a sugar and surfactant respectively
WO2004073733A1 (en) * 2003-02-24 2004-09-02 Morinaga Milk Industry Co., Ltd. Interleukin 6 production inhibitor
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
JP4651541B2 (en) * 2003-10-17 2011-03-16 中外製薬株式会社 Mesothelioma treatment
US8617550B2 (en) 2003-12-19 2013-12-31 Chugai Seiyaku Kabushiki Kaisha Treatment of vasculitis with IL-6 antagonist
WO2005090405A1 (en) 2004-03-24 2005-09-29 Chugai Seiyaku Kabushiki Kaisha Subtype of humanized antibody against interleukin-6 receptor
AR048335A1 (en) 2004-03-24 2006-04-19 Chugai Pharmaceutical Co Ltd THERAPEUTIC AGENTS FOR INTERNAL EAR DISORDERS CONTAINING AN IL-6 ANTAGONIST AS AN ACTIVE INGREDIENT
WO2006106905A1 (en) 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
KR101502920B1 (en) * 2005-06-21 2015-03-17 조마 (유에스) 엘엘씨 IL-1β Binding antibodies and fragments thereof
EP1941907B1 (en) 2005-10-14 2016-03-23 Fukuoka University Inhibitor of transplanted islet dysfunction in islet transplantation
AU2006305119B2 (en) * 2005-10-21 2012-12-20 Chugai Seiyaku Kabushiki Kaisha Agents for treating cardiopathy
AR057582A1 (en) 2005-11-15 2007-12-05 Nat Hospital Organization AGENTS TO DELETE INDUCTION OF CYTOTOXIC T LYMPHOCYTES
EP3135298B1 (en) * 2006-01-27 2018-06-06 Keio University Therapeutic agents for diseases involving choroidal neovascularization
EP2006381B1 (en) 2006-03-31 2016-02-03 Chugai Seiyaku Kabushiki Kaisha Method for controlling blood pharmacokinetics of antibodies
CN105177091A (en) 2006-03-31 2015-12-23 中外制药株式会社 Antibody modification method for purifying bispecific antibody
WO2007116962A1 (en) 2006-04-07 2007-10-18 Osaka University Muscle regeneration promoter
US8080248B2 (en) 2006-06-02 2011-12-20 Regeneron Pharmaceuticals, Inc. Method of treating rheumatoid arthritis with an IL-6R antibody
US7582298B2 (en) 2006-06-02 2009-09-01 Regeneron Pharmaceuticals, Inc. High affinity antibodies to human IL-6 receptor
CN101528778A (en) * 2006-08-18 2009-09-09 埃博灵克斯股份有限公司 Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling
US8629244B2 (en) 2006-08-18 2014-01-14 Ablynx N.V. Interleukin-6 receptor binding polypeptides
US9725514B2 (en) 2007-01-23 2017-08-08 Shinshu University Chronic rejection inhibitor
US8178101B2 (en) 2007-05-21 2012-05-15 Alderbio Holdings Inc. Use of anti-IL-6 antibodies having specific binding properties to treat cachexia
US20090238825A1 (en) * 2007-05-21 2009-09-24 Kovacevich Brian R Novel rabbit antibody humanization methods and humanized rabbit antibodies
US8404235B2 (en) 2007-05-21 2013-03-26 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US7906117B2 (en) * 2007-05-21 2011-03-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
US8252286B2 (en) 2007-05-21 2012-08-28 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US8062864B2 (en) 2007-05-21 2011-11-22 Alderbio Holdings Llc Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
US9701747B2 (en) 2007-05-21 2017-07-11 Alderbio Holdings Llc Method of improving patient survivability and quality of life by anti-IL-6 antibody administration
MX2009012493A (en) * 2007-05-21 2010-01-20 Alder Biopharmaceuticals Inc Novel rabbit antibody humanization methods and humanized rabbit antibodies.
ES2610607T3 (en) 2007-05-21 2017-04-28 Alderbio Holdings Llc Antibodies against IL-6 and their uses
EP4368721A2 (en) 2007-09-26 2024-05-15 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in cdr
WO2009041621A1 (en) 2007-09-26 2009-04-02 Chugai Seiyaku Kabushiki Kaisha Anti-il-6 receptor antibody
US9688762B2 (en) 2007-09-26 2017-06-27 Chugai Sciyaku Kabushiki Kaisha Modified antibody constant region
CN101939424B (en) * 2007-12-05 2016-12-28 中外制药株式会社 Anti-NR10 antibody and application thereof
PE20091174A1 (en) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd LIQUID FORMULATION WITH HIGH CONCENTRATION OF ANTIBODY CONTENT
NO2708559T3 (en) 2008-04-11 2018-08-25
CA2724279C (en) 2008-05-13 2017-03-07 Novimmune S.A. Anti-il-6/il-6r antibodies and methods of use thereof
JP5544290B2 (en) 2008-06-05 2014-07-09 独立行政法人国立がん研究センター Nerve infiltration inhibitor
TWI440469B (en) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
US8992920B2 (en) 2008-11-25 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of arthritis
US9452227B2 (en) * 2008-11-25 2016-09-27 Alderbio Holdings Llc Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
US8420089B2 (en) 2008-11-25 2013-04-16 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US9212223B2 (en) 2008-11-25 2015-12-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US8323649B2 (en) * 2008-11-25 2012-12-04 Alderbio Holdings Llc Antibodies to IL-6 and use thereof
US8337847B2 (en) 2008-11-25 2012-12-25 Alderbio Holdings Llc Methods of treating anemia using anti-IL-6 antibodies
RU2524152C2 (en) * 2009-03-19 2014-07-27 Чугаи Сейяку Кабусики Кайся Medication for treatment of rheumatoid arthritis
TWI646193B (en) 2009-03-19 2019-01-01 中外製藥股份有限公司 Antibody constant region alteration
EP2409991B1 (en) 2009-03-19 2017-05-03 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
US10618964B2 (en) 2009-04-10 2020-04-14 Ablynx N.V. Nanobody against IL-6R
CN105399828B (en) 2009-04-10 2021-01-15 埃博灵克斯股份有限公司 Improved amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of IL-6R related diseases and disorders
TW201041595A (en) 2009-05-15 2010-12-01 Chugai Pharmaceutical Co Ltd Anti-axl antibody
JP5837821B2 (en) 2009-09-24 2015-12-24 中外製薬株式会社 Antibody constant region variants
EP4406615A2 (en) 2009-10-26 2024-07-31 F. Hoffmann-La Roche AG Method for the production of a glycosylated immunoglobulin
US9775921B2 (en) 2009-11-24 2017-10-03 Alderbio Holdings Llc Subcutaneously administrable composition containing anti-IL-6 antibody
US9724410B2 (en) 2009-11-24 2017-08-08 Alderbio Holdings Llc Anti-IL-6 antibodies or fragments thereof to treat or inhibit cachexia, associated with chemotherapy toxicity
JO3417B1 (en) 2010-01-08 2019-10-20 Regeneron Pharma Stabilized formulations containing anti-interleukin-6 receptor (il-6r) antibodies
TWI609698B (en) 2010-01-20 2018-01-01 Chugai Pharmaceutical Co Ltd Stabilized antibody-containing solution preparation
EP2543730B1 (en) 2010-03-04 2018-10-31 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
HUE060454T2 (en) * 2010-05-28 2023-03-28 Chugai Pharmaceutical Co Ltd Antitumor t cell response enhancer
EP2578233B1 (en) 2010-05-28 2017-04-26 National Cancer Center Therapeutic agent for pancreatic cancer
CN104998254A (en) 2010-11-08 2015-10-28 基因技术公司 Subcutaneously administered anti-IL-6 receptor antibodies
BR112013012213A2 (en) 2010-11-17 2020-09-01 Chugai Seiyaku Kabushiki Kaisha multi-specific antigen-binding molecules having an alternative function to the function of factors viii, ix ex of blood coagulation, and bispecific antibody, their uses in the prevention or treatment of hemorrhage, nucleic acid, vector, cell, method to produce the aforementioned binding molecules, pharmaceutical composition and kit
AU2011332817A1 (en) 2010-11-23 2013-06-13 Alder Biopharmaceuticals, Inc. Anti-IL-6 antibodies for the treatment of anemia
AU2011337704B2 (en) 2010-11-30 2017-06-15 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
PL3326648T3 (en) 2011-01-28 2021-10-11 Sanofi Biotechnology Pharmaceutical compositions comprising human antibodies to pcsk9
KR20200103845A (en) 2011-02-25 2020-09-02 추가이 세이야쿠 가부시키가이샤 FcγRIIb-specific Fc antibody
AR087305A1 (en) 2011-07-28 2014-03-12 Regeneron Pharma STABILIZED FORMULATIONS CONTAINING ANTI-PCSK9 ANTIBODIES, PREPARATION METHOD AND KIT
AU2012311443B2 (en) 2011-09-23 2016-12-01 Ablynx Nv Prolonged inhibition of interleukin-6 mediated signaling
TW201817744A (en) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 Therapeutic antigen-binding molecule with a FcRn-binding domain that promotes antigen clearance
EP3939996A1 (en) 2011-09-30 2022-01-19 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
TWI589299B (en) 2011-10-11 2017-07-01 再生元醫藥公司 Compositions for the treatment of rheumatoid arthritis and methods of using same
PL2818478T3 (en) 2011-10-28 2017-09-29 Regeneron Pharmaceuticals, Inc. Humanized IL-6 and IL-6 receptor
KR101487935B1 (en) 2012-05-21 2015-02-02 한국생명공학연구원 A pharmaceutical composition comprising extract or fraction of Salvia plebeia R. Br. for preventing or treating STAT3-mediated disease
US10822420B2 (en) * 2012-09-13 2020-11-03 Chugai Seiyaku Kabushiki Kaisha Gene knock-in non-human animal
US10782290B2 (en) 2013-06-11 2020-09-22 National Center Of Neurology And Psychiatry Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (RRMS) patient, and method for determining applicability of novel therapy
MX363403B (en) 2013-07-04 2019-03-22 Hoffmann La Roche Interference-suppressed immunoassay to detect anti-drug antibodies in serum samples.
RU2730594C2 (en) 2013-09-27 2020-08-24 Чугаи Сейяку Кабусики Кайся Method of producing a polypeptide heteromultiters
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
MA40764A (en) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd THERAPEUTIC AGENT INDUCING CYTOTOXICITY
JP2017534617A (en) 2014-10-21 2017-11-24 アブリンクス エン．ヴェー． Treatment of IL-6R related diseases
SI3233921T1 (en) 2014-12-19 2022-01-31 Chugai Seiyaku Kabushiki Kaisha Anti-c5 antibodies and methods of use
CA2963760A1 (en) 2014-12-19 2016-06-23 Yoshinao Ruike Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
SG10201907215QA (en) 2015-02-05 2019-09-27 Chugai Pharmaceutical Co Ltd Antibodies Comprising An Ion Concentration Dependent Antigen-Binding Domain, Fc Region Variants, Il-8-Binding Antibodies, And Uses Therof
PL3263132T3 (en) 2015-02-27 2024-04-15 Chugai Seiyaku Kabushiki Kaisha Composition for treating il-6-related diseases
EP3279216A4 (en) 2015-04-01 2019-06-19 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide hetero-oligomer
JP6875683B2 (en) 2015-05-19 2021-05-26 国立研究開発法人国立精神・神経医療研究センター How to determine the application of new treatment for multiple sclerosis (MS) patients
JP7128460B2 (en) 2015-06-04 2022-08-31 国立研究開発法人国立精神・神経医療研究センター Psychiatric disorder therapeutic agent containing IL-6 inhibitor as an active ingredient
EA201890519A1 (en) 2015-08-18 2018-07-31 Ридженерон Фармасьютикалз, Инк. INHIBITING ANTIBODIES AGAINST PCSK9 FOR THE TREATMENT OF PATIENTS WITH HYPERLIPIDEMIA EXPOSING TO LIPOPROTEIN SCARVA
WO2017087708A1 (en) 2015-11-19 2017-05-26 The Brigham And Women's Hospital, Inc. Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity
WO2017110981A1 (en) 2015-12-25 2017-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
EP3398965A4 (en) 2015-12-28 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Method for promoting efficiency of purification of fc region-containing polypeptide
US11484591B2 (en) 2016-02-22 2022-11-01 Ohio State Innovation Foundation Chemoprevention using controlled-release formulations of anti-interleukin 6 agents, synthetic vitamin A analogues or metabolites, and estradiol metabolites
SG11201807936VA (en) 2016-03-14 2018-10-30 Chugai Pharmaceutical Co Ltd Cell injury inducing therapeutic drug for use in cancer therapy
CA3026050A1 (en) 2016-08-05 2018-02-08 Chugai Seiyaku Kabushiki Kaisha Composition for prophylaxis or treatment of il-8 related diseases
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
JP7191833B2 (en) 2017-01-30 2022-12-19 中外製薬株式会社 Anti-sclerostin antibodies and uses thereof
AU2018234844B2 (en) 2017-03-17 2024-01-25 Ohio State Innovation Foundation Nanoparticles for delivery of chemopreventive agents
US11851486B2 (en) 2017-05-02 2023-12-26 National Center Of Neurology And Psychiatry Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
KR20200074160A (en) 2017-10-20 2020-06-24 가꼬우호우징 효고 이카다이가쿠 Pharmaceutical composition for inhibiting post-surgical adhesion containing anti-IL-6 receptor antibody
WO2019177543A1 (en) 2018-03-15 2019-09-19 Chugai Seiyaku Kabushiki Kaisha Anti-dengue virus antibodies having cross-reactivity to zika virus and methods of use
KR20210122810A (en) 2019-01-31 2021-10-12 사노피 바이오테크놀로지 Anti-IL-6 receptor antibody for the treatment of juvenile idiopathic arthritis
EP3947737A2 (en) 2019-04-02 2022-02-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions
CN117247451B (en) * 2023-11-17 2024-02-09 中国人民解放军军事科学院军事医学研究院 Single-domain antibody for human interleukin 6 protein and application thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670373A (en) * 1988-01-22 1997-09-23 Kishimoto; Tadamitsu Antibody to human interleukin-6 receptor
US5171840A (en) 1988-01-22 1992-12-15 Tadamitsu Kishimoto Receptor protein for human B cell stimulatory factor-2
US5814307A (en) * 1989-04-10 1998-09-29 Bristol-Myers Squibb Company Method for regulating cell growth, leukocyte differentiation and tumor cell growth using Oncostatin M to stimulate synthesis of IL-6
US5216128A (en) * 1989-06-01 1993-06-01 Yeda Research And Development Co., Ltd. IFN-β2/IL-6 receptor its preparation and pharmaceutical compositions containing it
CA2021594C (en) * 1989-07-20 2002-01-08 Tadamitsu Kishimoto Antibody to human interleukin-6 receptor
JPH03155795A (en) * 1989-11-13 1991-07-03 Chuzo Kishimoto Mouse-interleukin-6 receptor protein
JP3045172B2 (en) * 1990-05-19 2000-05-29 岸本 忠三 Chemical method for measuring human IL-6 using IL-6 receptor and kit therefor
JP3212597B2 (en) * 1990-08-01 2001-09-25 忠三 岸本 Human IL-6 receptor immunochemical assay and assay kit
JPH04187645A (en) * 1990-11-22 1992-07-06 Chuzo Kishimoto Agent for suppressing action of interleukin 6
JPH05227970A (en) * 1992-02-19 1993-09-07 Chugai Pharmaceut Co Ltd Reconstructed human antibody to human interleukin-6 receptor
DK0628639T3 (en) * 1991-04-25 2000-01-24 Chugai Pharmaceutical Co Ltd Reconstituted human antibody to human interleukin-6 receptor
JP3258348B2 (en) * 1991-08-02 2002-02-18 東ソー株式会社 HIV infection inhibitor
FR2694767B1 (en) * 1992-08-13 1994-10-21 Innotherapie Lab Sa Anti-IL6R monoclonal antibodies, and their applications.
CA2142989A1 (en) * 1992-08-21 1994-03-03 Glenn H. Bock A novel b-lymphoma cell line and antigen
JP3525221B2 (en) * 1993-02-17 2004-05-10 味の素株式会社 Immunosuppressants
US5888510A (en) * 1993-07-21 1999-03-30 Chugai Seiyaku Kabushiki Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
US5759546A (en) * 1994-02-04 1998-06-02 Weinberg; Andrew D. Treatment of CD4 T-cell mediated conditions
EP0811384B1 (en) * 1995-02-13 2006-06-21 Chugai Seiyaku Kabushiki Kaisha Muscle protein decomposition inhibitor containing il-6 receptor antibody
US20020187150A1 (en) * 1997-08-15 2002-12-12 Chugai Seiyaku Kabushiki Kaisha Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient
PL201461B1 (en) * 1998-03-17 2009-04-30 Chugai Pharmaceutical Co Ltd Preventives or remedies for inflammatory intestinal diseases containing as the active ingredient il-6 antagonists
JP4889187B2 (en) * 2000-10-27 2012-03-07 中外製薬株式会社 A blood MMP-3 concentration reducing agent comprising an IL-6 antagonist as an active ingredient
UA80091C2 (en) * 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
NZ535748A (en) * 2002-04-12 2007-06-29 Pfizer Use of EP4 receptor ligands in the treatment of IL-6 involved diseases
GB2401040A (en) * 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases

Similar Documents

Publication Publication Date Title
RU97108070A (en) PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF DISEASES CAUSED BY IL-6 EDUCATION
CA2203182A1 (en) Remedy for diseases caused by il-6 production
IT1245748B (en) PREPARATION INCLUDING BIOTINYLATE MONOCLONAL ANTIBODIES, AVIDIN AND BIOTIN, FOR DIAGNOSIS OF CANCER DISEASES AND ITS USE
FI963101A0 (en) Use of anti-TNF antibodies as drugs for the treatment of diseases in which serum interleukin-6 levels are elevated
EA201300022A1 (en) THERAPEUTIC HUMAN MONOCLONAL ANTIBODY AGAINST IL-1R1
DE69333299D1 (en) Drugs that increase the synaptic response mediated by AMPA receptors
RU2008102979A (en) THERAPEUTIC FOR DISEASES RELATED TO CHILD CHRONIC ARTHRITIS DISEASES
HUP0402653A2 (en) Human antibodies specific for interleukin 15 (il-15)
ES2167391T3 (en) IMMUNOCONJUGADOS II.
DE69635730D1 (en) SYNTHESIS OF BREAST TUMOR ASSOCIATED ANTIGENS DEFINED BY THE MONOCLONAL ANTIBODY MBR1 AND ITS USE
YU81091A (en) ANALYSIS OF 5- (1-HYDROXY-2-PIPERIDINOPROPYL) -2- (1H, 3H) -INDOLONE
TR199901710T2 (en) IL-8 receptor antagonists.
TR199900318T2 (en) IL-8 receptor antagonists.
ES2061769T3 (en) MONOCLONAL ANTIBODY AND ITS USE.
IT1207589B (en) COMPOSITION OF CROSS-PROTECTIVE HUMAN MONOCLONAL ANTIBODIES.
DE69127947D1 (en) Monoclonal antibodies to human IgE
DE60221813D1 (en) THIAZOLOPYRIMIDIN DERIVATIVES AND THEIR USE AS ANTAGONISTS OF THE CX3CR1 RECEPTOR
BR0108867A (en) Il-8 Receptor Antagonists
FR2612736B1 (en) URBAN FURNITURE FOR THE COMFORT OF PETS
IT1239065B (en) MONOCLONAL ANTIBODY WHICH INHIBITS THE BIOLOGICAL ACTION OF THE PLATEN FACTOR 4
MX9207216A (en) 3-HYDROXYCHROMANES 6-SULFONIL SUBSTITUTED ETHANOL ADDECTS AND THEIR USE AS DISEASE INHALATION AGENTS.
ITMI911909A1 (en) SHAPED ELASTICIZED FABRIC FOR THE APPLICATION TO THE BODY OF ANIMALS SUBJECTED TO BIOTOSATURA.
MA18890A1 (en) SYNTHESIS OF ISOPROPYLAMINO-2 PYRIMIDINE
RU99127290A (en) TARAPEUTIC AGENT FOR TREATMENT OF CACHEXIA
RU2227748C2 (en) Therapeutic agent for treatment of cachexia